Integra LifeSciences (NASDAQ:IART) Downgraded to “Hold” Rating by Wall Street Zen

Integra LifeSciences (NASDAQ:IART) was downgraded by Wall Street Zen from a “buy” rating to a “hold” rating in a note issued to investors on Saturday.

IART has been the subject of a number of other research reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Integra LifeSciences in a research report on Monday, December 29th. Wells Fargo & Company lowered their price target on Integra LifeSciences from $13.00 to $12.00 and set an “equal weight” rating on the stock in a report on Friday, February 27th. Two analysts have rated the stock with a Buy rating, two have issued a Hold rating and three have assigned a Sell rating to the company’s stock. According to MarketBeat.com, Integra LifeSciences currently has a consensus rating of “Reduce” and an average price target of $14.80.

Integra LifeSciences Trading Down 1.6%

Shares of NASDAQ IART opened at $9.73 on Friday. Integra LifeSciences has a 1 year low of $9.36 and a 1 year high of $24.36. The company has a debt-to-equity ratio of 1.66, a current ratio of 2.54 and a quick ratio of 1.46. The firm has a 50-day moving average of $11.72 and a 200 day moving average of $13.06. The stock has a market cap of $758.36 million, a P/E ratio of -1.45 and a beta of 1.02.

Integra LifeSciences (NASDAQ:IART) last posted its quarterly earnings data on Thursday, February 26th. The life sciences company reported $0.83 earnings per share for the quarter, beating analysts’ consensus estimates of $0.79 by $0.04. Integra LifeSciences had a positive return on equity of 14.76% and a negative net margin of 31.58%.The company had revenue of $434.93 million during the quarter, compared to analyst estimates of $429.62 million. During the same quarter last year, the company earned $0.97 EPS. The firm’s revenue for the quarter was down 1.7% on a year-over-year basis. Integra LifeSciences has set its Q1 2026 guidance at 0.370-0.450 EPS and its FY 2026 guidance at 2.300-2.400 EPS. As a group, sell-side analysts expect that Integra LifeSciences will post 2.45 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Rubric Capital Management LP grew its holdings in Integra LifeSciences by 58.4% during the 2nd quarter. Rubric Capital Management LP now owns 7,353,934 shares of the life sciences company’s stock worth $90,233,000 after acquiring an additional 2,710,262 shares in the last quarter. Paradigm Capital Management Inc. NY increased its position in Integra LifeSciences by 57.5% during the 2nd quarter. Paradigm Capital Management Inc. NY now owns 2,181,500 shares of the life sciences company’s stock valued at $26,767,000 after purchasing an additional 796,300 shares during the period. Invenomic Capital Management LP raised its holdings in shares of Integra LifeSciences by 78.3% in the 4th quarter. Invenomic Capital Management LP now owns 1,055,941 shares of the life sciences company’s stock valued at $13,115,000 after purchasing an additional 463,729 shares in the last quarter. Kotler Kevin bought a new stake in shares of Integra LifeSciences in the 4th quarter valued at about $5,309,000. Finally, SG Americas Securities LLC purchased a new stake in shares of Integra LifeSciences in the 4th quarter worth approximately $4,722,000. Hedge funds and other institutional investors own 84.78% of the company’s stock.

About Integra LifeSciences

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.